This is a match-making section for JPIAMR 17th call - AMR Interventions 2024 (IMPACT).
Human Health
Pseudomonas aeruginosa antibiotic resistance collateral sensitivity evolutionary robustness trade-offs of evolution
The research line I am leading at CNB (CSIC) consists in the design of therapeutic strategies, based on evolutionary robustness, to treat P. aeruginosa infections using existing antibiotics.
Topic 2: Improve treatments aiming to prevent or reduce the emergence of antibacterial resistance. Specifically, discovery of new therapeutic alternatives. Human health. IMPORTANT: Looking for a Spanish clinical partner (see below). "Public Research Institutions can only participate if they apply together with hospitals, primary health care or public health administration of the Spanish National Health System (or Accredited Health Research Institutes (IIS) in the same proposal. It is not allowed for these entities to apply independently, thus there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal."
Submitted on 2024-01-30 18:55:58
« Return to the partner search tool